Sevim Bavbek1, Seçil Kepil Özdemir2, Beyza Doğanay Erdoğan3, Işıl Karaboğa4, Suna Büyüköztürk5, Aslı Gelincik5, İnsu Yılmaz6, Özlem Göksel7, Adile Berna Dursun8, Gül Karakaya9, Ali Fuat Kalyoncu9, Ferhan Özşeker10, Gülden Paşaoğlu Karakış11, Ferda Öner Erkekol12, Gözde Köycü12, Metin Keren12, Ilaria Baiardini13, Antonino Romano14. 1. Department of Chest Diseases, Division of Allergy and Immunology, Ankara University School of Medicine, Ankara, Turkey. sevim.bavbek@medicine.ankara.edu.tr. 2. Department of Internal Medicine, Division of Allergy and Immunology, Adnan Menderes University School of Medicine, Aydın, Turkey. 3. Department of Biostatistics, Ankara University School of Medicine, Ankara, Turkey. 4. Department of Psychiatry, Ankara University School of Medicine, Ankara, Turkey. 5. Department of Internal Medicine, Division of Allergy and Immunology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey. 6. Department of Chest Diseases, Division of Allergy and Immunology, Erciyes University School of Medicine, Kayseri, Turkey. 7. Department of Pulmonary Medicine, Asthma and Allergy Unit, Ege University School of Medicine, Izmir, Turkey. 8. Department of Internal Medicine, Division of Allergy and Immunology, Recep Tayyip Erdoğan University School of Medicine, Rize, Turkey. 9. Department of Chest Diseases, Division of Allergy and Immunology, Hacettepe University School of Medicine, Ankara, Turkey. 10. Department of Chest Diseases, Division of Allergy and Immunology, Süreyyapaşa Chest Diseases and Thoracic Surgery Training and Research Hospital, İstanbul, Turkey. 11. , İstanbul, Turkey. 12. Department of Chest Diseases, Division of Allergy and Immunology, Atatürk Chest Diseases and Thoracic Surgery Training and Research Hospital, Ankara, Turkey. 13. Allergy and Respiratory Diseases Clinic - DIMI, University of Genoa, IRCCS AOU San Martino-IST, Genoa, Italy. 14. Allergy Unit, Complesso Integrato Columbus, Rome, Italy.
Abstract
PURPOSE: The first disease-specific quality-of-life questionnaire in patients with drug hypersensitivity, Drug Hypersensitivity Quality of Life Questionnaire (DrHy-Q), was developed and validated recently. The aim of this study was to assess validity, reliability and responsiveness to interventions of the Turkish version of the DrHy-Q. METHODS: The Turkish version of the DrHy-Q was administered to prospectively enrolled 736 patients with drug hypersensitivity from ten allergy units. To assess validity, all patients completed the validated Turkish version of Psychological General Well-Being Index (PGWBI). For test-retest reliability, 182 patients completed the DrHy-Q 1 week after the first questionnaire administration without any intervention. Responsiveness was assessed on 97 patients who had a DrHy-Q recorded at a follow-up visit after the intervention. RESULTS: The internal consistency and test-retest reliability of the scale were adequate (Cronbach's alpha = 0.934, intra-class correlation coefficient = 0.783). The DrHy-Q scores showed weak negative correlations with the PGWBI total and domain scores (r = - 0.378 to -0.254, p < 0.001). DrHy-Q was able to discriminate the patients with one drug hypersensitivity reaction from the patients with two and above two reactions (p = 0.012 and p < 0.001, respectively), and the patients who experienced a respiratory reaction from the patients who did not (p = 0.018). However, it did not discriminate the patients with comorbid disease including psychiatric comorbidity (p > 0.05). The baseline DrHy-Q scores were significantly higher than the post-intervention scores (p = 0.008). CONCLUSION: The Turkish version of DrHy-Q is reliable and valid for evaluating quality of life in patients with drug hypersensitivity, and it appeared responsive to interventions.
PURPOSE: The first disease-specific quality-of-life questionnaire in patients with drug hypersensitivity, Drug Hypersensitivity Quality of Life Questionnaire (DrHy-Q), was developed and validated recently. The aim of this study was to assess validity, reliability and responsiveness to interventions of the Turkish version of the DrHy-Q. METHODS: The Turkish version of the DrHy-Q was administered to prospectively enrolled 736 patients with drug hypersensitivity from ten allergy units. To assess validity, all patients completed the validated Turkish version of Psychological General Well-Being Index (PGWBI). For test-retest reliability, 182 patients completed the DrHy-Q 1 week after the first questionnaire administration without any intervention. Responsiveness was assessed on 97 patients who had a DrHy-Q recorded at a follow-up visit after the intervention. RESULTS: The internal consistency and test-retest reliability of the scale were adequate (Cronbach's alpha = 0.934, intra-class correlation coefficient = 0.783). The DrHy-Q scores showed weak negative correlations with the PGWBI total and domain scores (r = - 0.378 to -0.254, p < 0.001). DrHy-Q was able to discriminate the patients with one drug hypersensitivity reaction from the patients with two and above two reactions (p = 0.012 and p < 0.001, respectively), and the patients who experienced a respiratory reaction from the patients who did not (p = 0.018). However, it did not discriminate the patients with comorbid disease including psychiatric comorbidity (p > 0.05). The baseline DrHy-Q scores were significantly higher than the post-intervention scores (p = 0.008). CONCLUSION: The Turkish version of DrHy-Q is reliable and valid for evaluating quality of life in patients with drug hypersensitivity, and it appeared responsive to interventions.
Entities:
Keywords:
Disease-specific questionnaires; Drug allergy; Drug hypersensitivity; Quality of life
Authors: I Baiardini; M Pasquali; A Giardini; C Specchia; G Passalacqua; S Venturi; F Braido; S Bonini; G Majani; G W Canonica Journal: Allergy Date: 2003-04 Impact factor: 13.146
Authors: F Estelle R Simons; Ledit R F Ardusso; M Beatrice Bilò; Yehia M El-Gamal; Dennis K Ledford; Johannes Ring; Mario Sanchez-Borges; Gian Enrico Senna; Aziz Sheikh; Bernard Y Thong Journal: J Allergy Clin Immunol Date: 2011-03 Impact factor: 10.793
Authors: I Baiardini; P J Bousquet; Z Brzoza; G W Canonica; E Compalati; A Fiocchi; W Fokkens; R G van Wijk; S La Grutta; C Lombardi; M Maurer; A M Pinto; E Ridolo; G E Senna; I Terreehorst; A Todo Bom; J Bousquet; T Zuberbier; F Braido Journal: Allergy Date: 2009-11-20 Impact factor: 13.146
Authors: I Ertam; G Kitapcioglu; K Aksu; G Keser; A Ozaksar; H Elbi; I Unal; S Alper Journal: Clin Exp Rheumatol Date: 2009 Mar-Apr Impact factor: 4.473
Authors: P Demoly; N F Adkinson; K Brockow; M Castells; A M Chiriac; P A Greenberger; D A Khan; D M Lang; H-S Park; W Pichler; M Sanchez-Borges; T Shiohara; B Y- H Thong Journal: Allergy Date: 2014-04 Impact factor: 13.146
Authors: Julie F Pallant; Anne-Maree Keenan; Roseanne Misajon; Philip G Conaghan; Alan Tennant Journal: Health Qual Life Outcomes Date: 2009-04-29 Impact factor: 3.186
Authors: E Dias de Castro; J Barbosa; A M Mesquita; A Caires; L Ribeiro; J R Cernadas; I Baiardini Journal: Health Qual Life Outcomes Date: 2021-05-10 Impact factor: 3.186